NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA
Biocryst Pharmaceuticals Inc is a mid cap company (market value between $2 billion and $10 billion) in the Drug Manufacturers - Specialty & Generic industry.
BioCryst Pharmaceuticals is a biotechnology company developing and commercializing medicines for hereditary angioedema and other rare diseases. The company markets ORLADEYO, an oral therapy for preventing HAE attacks, along with approved influenza treatments RAPIVAB, RAPIACTA, and PERAMIFLU. BioCryst also pursues a pipeline of oral and injectable therapeutics for rare diseases through internal discovery and business development.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Biocryst Pharmaceuticals Inc stock.
Undervalued: intrinsic value $38.99 per share, market price $8.47, margin of safety 78.3% (as of 2026-10-30).
Discounting its cash flows at 8.4% (average of 2 methods) values the shares at $38.99; the price of $8.47 is 78% below that value, and 79% of that value comes from beyond year five.
Leak Score: 86/100 on 10 of 12 signals (Strong Leak).
17 more funds hold it; the full list is part of the paid plan.
All 84 Drug Manufacturers - Specialty & Generic stocks
BCRX is undervalued (as of the 2026-10-30 close). Discounting its cash flows at 8.4% (average of 2 methods) values the shares at $38.99; the price of $8.47 is 78% below that value, and 79% of that value comes from beyond year five.
$38.99 per share (as of the 2026-10-30 close), against a market price of $8.47. That is a margin of safety of 78.3%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
86 out of 100, which we rate "Strong Leak", on 10 of 12 value investing signals.